CTC immune escape mediated by PD-L1

被引:37
|
作者
Wang, Xuefei
Sun, Qiang
Liu, Qiaofei
Wang, Changjun
Yao, Ru
Wang, Yimin
机构
[1] Chinese Acad Med Sci, Breast Surg Dept, Beijing, Peoples R China
[2] Peking Union Med Coll, Peking Union Med Coll & Hosp, Beijing, Peoples R China
[3] Shanxi Prov Peoples Hosp, Xian, Shaanxi, Peoples R China
关键词
BREAST-CANCER; CELLS; SUPPRESSION;
D O I
10.1016/j.mehy.2016.05.022
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Breast cancer is the most common malignant tumor in women around the world. Most breast cancer related deaths are from CTC (circulating tumor cells) metastasis. CTC is associated with the breast cancer patients' prognosis. But recently, circulating clusters were found and its metastasis and tumor formation ability is 23-50 times as CTC. However, its mechanism has not been clarified. These days, researchers have successfully completed CTC cluster separation, CTC cell culture, and PD-L1 was found to be related with histological grading of tumor. Meanwhile, the high expression of PD-L1 in CTC surface has also been reported. Since PD-L1 can mediate Treg to play the role of immunosuppression, we propose that CTC with positive PD-L1 is easier to connect PD-L1, immune cells (Treg regulatory T cells, MDSC bone marrow inhibitory cells) and CM cytokines etc. On one hand, Treg cells can protect CTC from being attacked by the immune system through the immunosuppression, on the other hand, they can weaken CTL killing ability and trigger more MDSC. Finally, CTC formed the metastatic lesion. (C) 2016 Elsevier Ltd. All rights reserved.
引用
收藏
页码:138 / 139
页数:2
相关论文
共 50 条
  • [21] Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
    Fei Tang
    Pan Zheng
    Cell & Bioscience, 8
  • [22] Expression of PD-L1 on renal tubular epithelial cells and functional role of PD-L1/PD-1 pathway in immune-mediated injury
    Wahl, PR
    Le Hir, M
    Heemann, U
    Wang, MH
    Schoop, R
    Wuthrich, RP
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 174A - 174A
  • [23] A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment
    Zhou, Tian C.
    Sankin, Alexander I.
    Porcelli, Steven A.
    Perlin, David S.
    Schoenberg, Mark P.
    Zang, Xingxing
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2017, 35 (01) : 14 - 20
  • [24] Tumor-derived microvesicles promote tumor immune escape through PD-1/PD-L1 interaction
    Kim, Dong Ha
    Choi, Yun Jung
    Kim, Seon Ye
    Lee, Jung-Eun
    Sung, Ki Jung
    Lee, Jae Cheol
    Rho, Jin Kyung
    CANCER RESEARCH, 2018, 78 (13)
  • [25] Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers
    Duruisseaux, Michael
    Rouquette, Isabelle
    Adam, Julien
    Cortot, Alexis
    Cazes, Aurelie
    Gibault, Laure
    Damotte, Diane
    Lantuejoul, Sylvie
    ANNALES DE PATHOLOGIE, 2017, 37 (01) : 61 - 78
  • [26] PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance
    Huang, Changsheng
    Ren, Shengxiang
    Chen, Yaqi
    Liu, Anyi
    Wu, Qi
    Jiang, Tao
    Lv, Panjing
    Song, Da
    Hu, Fuqing
    Lan, Jingqing
    Sun, Li
    Zheng, Xue
    Luo, Xuelai
    Chu, Qian
    Jia, Keyi
    Li, Yan
    Wang, Jun
    Zou, Caicun
    Hu, Junbo
    Wang, Guihua
    SCIENCE ADVANCES, 2023, 9 (21)
  • [27] Delta-tocotrienol disrupts PD-L1 glycosylation and reverses PD-L1-mediated immune suppression
    Sun, Zhenou
    Ma, Xuan
    Zhao, Chong
    Fan, Lihong
    Yin, Shutao
    Hu, Hongbo
    BIOMEDICINE & PHARMACOTHERAPY, 2024, 170
  • [28] BRD4 promotes immune escape of glioma cells by upregulating PD-L1 expression
    Liu, Yongsheng
    Cai, Lize
    Wang, Hao
    Yao, Lin
    Wu, Yue
    Zhang, Kai
    Su, Zuopeng
    Zhou, Youxin
    JOURNAL OF NEURO-ONCOLOGY, 2025, 171 (03) : 669 - 679
  • [29] PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies
    Frydenlund, Noah
    Mahalingam, Meera
    HUMAN PATHOLOGY, 2017, 66 : 13 - 33
  • [30] KRAS mutation- induced upregulation of PD-L1 mediates immune escape in lung adenocarcinoma
    Hong, S.
    Chen, N.
    Fang, W.
    Zhan, J.
    Zhang, L.
    ANNALS OF ONCOLOGY, 2016, 27